Drug News

March 2011 
Volume 41  Number 3
Pages 11 - 11
  PDF Version Available!

Healthcare providers are being alerted to a serious adverse reaction associated with dronedarone (Multaq), an antiarrhythmic used to treat atrial fibrillation and atrial flutter. Information about the potential, although rare, risk of severe hepatic injury is being added to the Warnings and Precautions and Adverse Reactions sections of dronedarone labels.The warning comes after two cases of acute liver failure leading to liver transplant were reported in patients receiving dronedarone. An FDA Safety Communication asks healthcare providers to inform patients taking the drug about the risk of hepatic injury or toxicity, and advise them to contact their healthcare provider immediately if they experience any signs and symptoms, such as jaundice, icterus, anorexia, and acholic stools while taking dronedarone. The FDA also asks healthcare providers to consider obtaining periodic liver panels, especially during the first 6 months of treatment. Adverse reactions to the drug should be reported

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events